Stock Track | Intellia Therapeutics Plummets 8.33% Intraday on Q1 Revenue Decline and Sector Weakness

Stock Track05-15

Intellia Therapeutics' stock plummeted 8.33% during intraday trading on Thursday, reflecting significant investor concern following the release of the company's latest financial results.

The sharp decline was primarily triggered by Intellia's first-quarter earnings report, which showed a concerning revenue contraction despite a narrower-than-expected loss. For the quarter, the company reported revenue of $15.048 million, a decrease of approximately 9.6% year-over-year. While the earnings per share loss of $0.81 beat market expectations, the revenue decline for this pre-commercial-stage biotech firm heightened market anxieties over its cash burn rate and the pace of its pipeline advancement.

Broader weakness in the biotechnology sector compounded the selling pressure on Intellia's shares, contributing to the overall negative sentiment during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168227460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 03:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168227460","market":"sg","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Plummets 8.33% Intraday on Q1 Revenue Decline and Sector Weakness","media":"Stock Track","content":"<p>Intellia Therapeutics' stock plummeted 8.33% during intraday trading on Thursday, reflecting significant investor concern following the release of the company's latest financial results.</p><p>The sharp decline was primarily triggered by Intellia's first-quarter earnings report, which showed a concerning revenue contraction despite a narrower-than-expected loss. For the quarter, the company reported revenue of $15.048 million, a decrease of approximately 9.6% year-over-year. While the earnings per share loss of $0.81 beat market expectations, the revenue decline for this pre-commercial-stage biotech firm heightened market anxieties over its cash burn rate and the pace of its pipeline advancement.</p><p>Broader weakness in the biotechnology sector compounded the selling pressure on Intellia's shares, contributing to the overall negative sentiment during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Plummets 8.33% Intraday on Q1 Revenue Decline and Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Plummets 8.33% Intraday on Q1 Revenue Decline and Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-15 03:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intellia Therapeutics' stock plummeted 8.33% during intraday trading on Thursday, reflecting significant investor concern following the release of the company's latest financial results.</p><p>The sharp decline was primarily triggered by Intellia's first-quarter earnings report, which showed a concerning revenue contraction despite a narrower-than-expected loss. For the quarter, the company reported revenue of $15.048 million, a decrease of approximately 9.6% year-over-year. While the earnings per share loss of $0.81 beat market expectations, the revenue decline for this pre-commercial-stage biotech firm heightened market anxieties over its cash burn rate and the pace of its pipeline advancement.</p><p>Broader weakness in the biotechnology sector compounded the selling pressure on Intellia's shares, contributing to the overall negative sentiment during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1168227460","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168227460","pubTimestamp":1778787472,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics' stock plummeted 8.33% during intraday trading on Thursday, reflecting significant investor concern following the release of the company's latest financial results.The sharp...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"个股追踪|Intellia Therapeutics盘中暴跌8.33%受Q1营收下滑及板块疲软影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics' stock plummeted 8.33% during intraday trading on Thursday, reflecting significant investor concern following the release of the company's latest financial results.The sharp decline was primarily triggered by Intellia's first-quarter earnings report, which showed a concerning revenue contraction despite a narrower-than-expected loss. For the quarter, the company reported revenue of $15.048 million, a decrease of approximately 9.6% year-over-year. While the earnings per share loss of $0.81 beat market expectations, the revenue decline for this pre-commercial-stage biotech firm heightened market anxieties over its cash burn rate and the pace of its pipeline advancement.Broader weakness in the biotechnology sector compounded the selling pressure on Intellia's shares, contributing to the overall negative sentiment during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168227460","isCrawlerRequest":true}